Zosano Pharma Corp., of Fremont, Calif., disclosed the publication regarding Adhesive Dermally-Applied Microarray (ADAM) technology for the delivery of the migraine drug zolmitriptan in the Journal of Pharmaceutics. The test evaluated how different in vitro skin models influenced the absorption of zolmitriptan with ADAM.